In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on Agios Pharma (AGIO – Research Report), ...

BofA lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $52 from $54 and keeps a Buy rating on the shares. While Q1 earnings ...

The market expects Agios Pharmaceuticals (AGIO) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known ...

The report covers 40+ companies and 50+ pipeline drugs. Explore drug profiles from clinical to nonclinical stages, assessment by product type, and detailed pipeline development activities. Key players ...

Currently, the analyst consensus on Agios Pharma is a Moderate Buy with an average price target of $56.17, representing a 106.96% upside. In a report released on April 3, RBC Capital also ...

The market expects Agios Pharmaceuticals (AGIO) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...